1426129-50-1对映异构体 | 153037-40-2

• 物质功能分类: 化学试剂 - 有机试剂 - 酯类
• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 1426129-50-1对映异构体
• 英文名称: (S)-2-(t-butoxycarbonylamino)-3-(biphenyl-4-yl)-propan-1-ol
• 英文别名: (S)-tert-butyl(1-([1,1'-biphenyl]-4-yl)-3-hydroxypropan-2-yl)carbamate；(S)-tert-butyl 1-(biphenyl-4-yl)-3-hydroxypropan-2-ylcarbamate；(S)-2-t-butoxycarbonylamino-3-(biphenyl-4-yl)-propan-1-ol；(S)-tert-Butyl (1-([1,1'-biphenyl]-4-yl)-3-hydroxypropan-2-yl)carbamate；tert-butyl N-[(2S)-1-hydroxy-3-(4-phenylphenyl)propan-2-yl]carbamate
• CAS: 153037-40-2
• 化学式: C₂₀H₂₅NO₃
• 分子量: 327.423
• InChiKey: TYQICOFAZDVKMK-SFHVURJKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  24
• 可旋转键数：
  7
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  58.6
• 氢给体数：
  2
• 氢受体数：
  3

安全信息

• 危险性防范说明：
  P261,P305+P351+P338
• 危险性描述：
  H302,H315,H319,H335

反应信息

• 作为反应物：
  描述：

  草酰氯 、 1426129-50-1对映异构体 、 乙氧甲酰基亚甲基三苯基膦 在 三乙胺 作用下， 以 正己烷 、 二氯甲烷 、 水 、 二甲基亚砜 为溶剂， 生成 (S)-4-(t-Butoxycarbonylamino)-5-(biphenyl-4-yl)-pentenoic acid ethyl ester
  参考文献：
  名称：

  Phosphono substituted tetrazole derivatives as ECE inhibitors

  摘要：

  本发明涉及公式##STR1##的N-磷酸甲基取代化合物。

  公开号：

  US05550119A1
• 作为产物：
  描述：

  N-叔丁氧羰基-3-(4-联苯基)-L-丙氨酸 在 三乙胺 、 sodium tetrahydroborate 作用下， 以 四氢呋喃 、 水 为溶剂， 反应 0.25h， 以77%的产率得到1426129-50-1对映异构体
  参考文献：
  名称：

  New thiazole carboxamides as potent inhibitors of Akt kinases

  摘要：

  A new series of 2-substituted thiazole carboxamides were identified as potent pan inhibitors against all three isoforms of Akt (Akt1, Akt2 and Akt3) by systematic optimization of weak screening hit N-(1-amino-3-phenylpropan-2-yl)-2-phenylthiazole-5-carboxamide (1). One of the most potent compounds, 5m, inhibited the kinase activities of Akt1, Akt2 and Akt3 with IC50 values of 25, 196 and 24 nM, respectively. The compound also potently inhibited the phosphorylation of downstream MDM2 and GSK3 beta proteins, and displayed strongly antiproliferative activity in prostate cancer cells. The inhibitors might serve as lead compounds for further development of novel effective anticancer agents. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.11.080

文献信息

• Phosphono/biaryl substituted amino acid derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05250522A1

  公开（公告）日：1993-10-05

  The present invention relates to the N-phosphonomethyl-biaryl substituted amino acid derivatives of formula I ##STR1## wherein X represents a direct bond, C.sub.1-4 -alkylene or C.sub.2 -C.sub.4 -alkenylene; R and R' represent independently hydrogen, carbocyclic aryl, 6-tetrahydronaphthyl, 5-indanyl, .alpha.-(trichloromethyl, carboxyl, esterified carboxyl or amidated carboxyl)substituted-(lower alkyl or aryl-lower alkyl), acyloxymethyl optionally monosubstituted on methyl carbon by C.sub.1-20 -alkyl, by C.sub.5 -C.sub.7 -cycloalkyl, by aryl or by aryl-lower alkyl; R.sub.1 represents monocyclic carbocyclic or monocyclic heterocyclic aryl; COR.sub.3 represents carboxyl or carboxyl derivatized in form of a pharmaceutically acceptable ester; R.sub.2 and R.sub.4 represent hydrogen, lower alkyl, trifluoromethyl, lower alkoxy or halogen; and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; methods for preparation of said compounds and for the preparation of intermediates; and methods of treating disorders in mammals which are responsive to the inhibition of neutral endopeptidases by administration of said compounds to mammals in need of such treatment.

  本发明涉及公式I的N-磷酸甲基-联苯取代氨基酸衍生物，其中X代表直接键，C.sub.1-4-烷基或C.sub.2-C.sub.4-烯基；R和R'独立地代表氢、碳环芳基、6-四氢萘基、5-茚基、α-(三氯甲基、羧基、酯化羧基或酰胺化羧基)取代-(较低烷基或芳基-较低烷基)、酰氧甲基，可选地在甲基碳上单取代为C.sub.1-20-烷基、C.sub.5-C.sub.7-环烷基、芳基或芳基-较低烷基；R.sub.1代表单环碳环芳基或单环杂环芳基；COR.sub.3代表羧基或以药学上可接受的酯形式衍生的羧基；R.sub.2和R.sub.4代表氢、较低烷基、三氟甲基、较低烷氧基或卤素；以及其药学上可接受的盐；包括所述化合物的药物组合物；制备所述化合物和中间体的方法；以及通过将所述化合物用于需要此类治疗的哺乳动物来抑制中性内肽酶以治疗哺乳动物的疾病的方法。
• 一种心衰药Ent resto 关键中间体(R)-叔丁基 (1-([1,1`-联苯]-4-基)-3-羟基丙烷-2-基) 氨基甲酸酯的制备方法
  申请人：上海皓元医药股份有限公司

  公开号：CN105017082B

  公开（公告）日：2017-09-19

  本发明涉及一种药物关键中间体的制备方法，具体涉及通过手性拆分制备(R)‑叔丁基(1‑([1,1'‑联苯]‑4‑基)‑3‑羟基丙烷‑2‑基)氨基甲酸酯的方法，本发明方法原料便宜易得，生产成本低；分离收率高，产品手性纯度高；3)操作简单，环境友好，适合工业生产。
• PHARMACEUTICAL COMPOSITIONS
  申请人：ZANDA Matteo

  公开号：US20110200581A1

  公开（公告）日：2011-08-18

  Synthesis natural tubulisine derivatives of formula (A) having a high cytotoxicity wherein: B is selected from CH 2 , CH 2 —CH 2 or CH 2 —CH 2 —CH 2 , D is an aromatic linker, X 1 is alkyl or alkenyl, X 2 is selected from the X 2a , substituted or non substituted, selected from: aryl, heteroaryl, arylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, or heteroarylalkyl, X 2b : alkylene-O-alkyl, wherein alkylene is C 2 -C 10 , X 2c : CH 2 —O-alkyl, X 3 is selected from H, or together with X 4 forms the group ═O, X 4 is selected from H, halogen, OH, SH, alkyl, alkenyl, (OR 5 ) n —OR 6 , OC(O)R 7 , NR 6 R 7 , or together with X 4 forms the group ═O, R 5 is an alkylene, n is zero or an integer from 1 to 10, R 6 and R 7 , equal to or different from each other, have the following meanings: z1: H, alkyl, z2 substituted or non substituted: aryl, heteroaryl, cycloalkyl, heterocycloalkyl, arylalkyl, heteroarylalkyl, cycloalkylalkyl, heterocycloalkylalkyl, X 5 is z2, or has the meaning of z3=alkyl, alkenyl, X 6 is selected from NR 8 R 9 , OR 8 , NH—NR 8 R 9 , SR 8 , R 10 , wherein R 8 and R 9 , equal to or different from each other, have the same meanings of R 8 , R 10 has the same meanings as R 6 but excluding H, X 7 is z3 or H, X 8 is selected from z3, H, halogen, OH, SH, OCH 3 .

  合成具有高细胞毒性的具有以下结构的天然管状素衍生物（A）其中：B从CH2、 — 或 — — 中选择，D是芳香连接体，X1是烷基或烯基，X2从X2a中选择，替代或未替代，从中选择：芳基、杂环芳基、芳基烷基、环烷基烷基、杂环烷基烷基或杂环芳基烷基，X2b：烷基氧烷基，其中烷基是C2-C10，X2c： —氧烷基，X3从H中选择，或与X4一起形成═O基团，X4从H、卤素、羟基、硫基、烷基、烯基、（OR5）n—OR6、OC（O）R7、NR6R7中选择，或与X4一起形成═O基团，R5是烷基，n为零或1至10之间的整数，R6和R7，彼此相等或不同，具有以下含义：z1：H、烷基，z2替代或未替代：芳基、杂环芳基、环烷基、杂环烷基、芳基烷基、杂环芳基烷基、环烷基烷基、杂环烷基烷基，X5是z2，或具有z3=烷基、烯基的含义，X6从NR8R9、OR8、NH—NR8R9、SR8、R10中选择，其中R8和R9，彼此相等或不同，具有R8的相同含义，R10具有与R6相同但不包括H的含义，X7是z3或H，X8从z3、H、卤素、羟基、硫基、OCH3中选择。
• [EN] PROCESS FOR PREPARATION OF N-BOC BIPHENYL ALANINOL<br/>[FR] PROCÉDÉ DE PRÉPARATION DE N-BOC ALANINOL BIPHÉNYLIQUE
  申请人：CHIRAL QUEST (SUZHOU) CO LTD

  公开号：WO2017059759A1

  公开（公告）日：2017-04-13

  A process is provided for preparation of (R)-N-Boc biphenyl alaninol.It provides a preparation process for a compound outlined as compound 4, which includes these operations: in one of the alcohol solvents, asymmetric hydrogenation of 5 in the presence of [Rh(Duanphos)(X)]Y and hydrogen to provide compound 4. Here "Duanphos" is (Rc,Sp)-Duanphos or (Sc,Rp)-Duanphos; X is NBD or/and COD; Y is one or more of BF4, PF6, SbF6. This process has a lot of advantages, such as low cost, safe operation, less pollution and high yield. The product was obtained in >99% purity and ee which is suitable to scale up in industrial scale.

  提供了一种制备（R）-N-Boc联苯丙氨醇的过程。该过程提供了一种用于制备化合物4的制备过程，包括以下操作：在其中一种醇溶剂中，在[Rh（Duanphos）（X）]Y的存在下进行5的不对称氢化反应和氢化反应，以提供化合物4。这里，“Duanphos”是（Rc，Sp）-Duanphos或（Sc，Rp）-Duanphos；X是NBD或/和COD；Y是BF4，PF6，SbF6中的一种或多种。该过程具有许多优点，例如低成本，安全操作，污染少和高产率。产物的纯度和ee均达到了>99％，适合在工业规模上扩大生产。
• Phosphono substituted tetrazole derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05273990A1

  公开（公告）日：1993-12-28

  The present invention relates to the N-phosphonomethyl substituted tetrazole derivatives of formula I ##STR1## and tautomers thereof wherein R.sub.1 is aryl or biaryl; n is zero, 1 or 2 pharmaceutically acceptable mono- or di-ester derivatives thereof in which one or both of the acidic hydroxy groups of the phosphono functional group are esterified in form of a pharmaceutically acceptable mono- or di-ester; and pharmaceutically acceptable salts thereof; pharmaceutical compositions comprising said compounds; methods for preparation of said compounds and for the preparation of intermediates; and methods of treating disorders in mammals which are responsive to the inhibition of neutral endopeptidases by administration of said compounds to mammals in need of such treatment.

  本发明涉及式I的N-磷酸甲基取代的四唑衍生物及其互变异构体，其中R1为芳基或联芳基；n为零、1或2，其药学上可接受的单酯或双酯衍生物，其中磷酸甲基功能团的一个或两个酸性羟基以药学上可接受的单酯或双酯形式酯化；以及其药学上可接受的盐；包括所述化合物的制药组合物；制备所述化合物和中间体的方法；以及通过将所述化合物用于需要此类治疗的哺乳动物的治疗中，抑制中性内肽酶的方法。